Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA38582
Max Phase: Preclinical
Molecular Formula: C16H20N4O
Molecular Weight: 284.36
Molecule Type: Small molecule
Associated Items:
ID: ALA38582
Max Phase: Preclinical
Molecular Formula: C16H20N4O
Molecular Weight: 284.36
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CN1C2CCC1CC(NC(=O)c1n[nH]c3ccccc13)C2
Standard InChI: InChI=1S/C16H20N4O/c1-20-11-6-7-12(20)9-10(8-11)17-16(21)15-13-4-2-3-5-14(13)18-19-15/h2-5,10-12H,6-9H2,1H3,(H,17,21)(H,18,19)
Standard InChI Key: PCQJPTSZYKYPDE-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 284.36 | Molecular Weight (Monoisotopic): 284.1637 | AlogP: 1.92 | #Rotatable Bonds: 2 |
Polar Surface Area: 61.02 | Molecular Species: BASE | HBA: 3 | HBD: 2 |
#RO5 Violations: 0 | HBA (Lipinski): 5 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 10.01 | CX Basic pKa: 9.10 | CX LogP: 0.96 | CX LogD: -0.43 |
Aromatic Rings: 2 | Heavy Atoms: 21 | QED Weighted: 0.89 | Np Likeness Score: -1.15 |
1. Fludzinski P, Evrard DA, Bloomquist WE, Lacefield WB, Pfeifer W, Jones ND, Deeter JB, Cohen ML.. (1987) Indazoles as indole bioisosteres: synthesis and evaluation of the tropanyl ester and amide of indazole-3-carboxylate as antagonists at the serotonin 5HT3 receptor., 30 (9): [PMID:3625701] [10.1021/jm00392a001] |
2. Bermudez J, Fake CS, Joiner GF, Joiner KA, King FD, Miner WD, Sanger GJ.. (1990) 5-Hydroxytryptamine (5-HT3) receptor antagonists. 1. Indazole and indolizine-3-carboxylic acid derivatives., 33 (7): [PMID:2362270] [10.1021/jm00169a016] |
3. Schaus JM, Thompson DC, Bloomquist WE, Susemichel AD, Calligaro DO, Cohen ML.. (1998) Synthesis and structure-activity relationships of potent and orally active 5-HT4 receptor antagonists: indazole and benzimidazolone derivatives., 41 (11): [PMID:9599243] [10.1021/jm970857f] |
4. Robertson DW, Bloomquist W, Cohen ML, Reid LR, Schenck K, Wong DT.. (1990) Synthesis and biochemical evaluation of tritium-labeled 1-methyl-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-1H-indazole-3-carboxa mide, a useful radioligand for 5HT3 receptors., 33 (12): [PMID:2258903] [10.1021/jm00174a013] |
5. Kaumann A, King F, Young R. (1992) Indazole as an indole bioisostere: 5-HT4 receptor antagonism., 2 (5): [10.1016/S0960-894X(00)80160-2] |
Source(1):